Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

✍ Scribed by Robert, Caroline; Ribas, Antoni; Wolchok, Jedd D; Hodi, F Stephen; Hamid, Omid; Kefford, Richard; Weber, Jeffrey S; Joshua, Anthony M; Hwu, Wen-Jen; Gangadhar, Tara C; Patnaik, Amita; Dronca, Roxana; Zarour, Hassane; Joseph, Richard W; Boasberg, Peter; Chmielowski, Bartosz; Mateus, Christine; Postow, Michael A; Gergich, Kevin; Elassaiss-Schaap, Jeroen; Li, Xiaoyun Nicole; Iannone, Robert; Ebbinghaus, Scot W; Kang, S Peter; Daud, Adil

• Book ID: 127103275
• Publisher: The Lancet
• Year: 2014
• Tongue: English
• Weight: 364 KB
• Volume: 384
• Category: Article
• ISSN: 0140-6736
• DOI: 10.1016/s0140-6736(14)60958-2